



Gentamicin Therapy and *MT-RNR1* Genotype

Laura Dean, MD¹

Created: April 29, 2015; Updated: August 1, 2018.

Introduction

Gentamicin is an aminoglycoside antibiotic that is commonly used to treat sepsis in premature infants. Brand names include Garamycin, Cidomycin, and Setpopal. Gentamicin is administered by injection to treat serious infections caused by Gram-negative bacteria (e.g., *Pseudomonas aeruginosa*, *Proteus* species, *Escherichia coli*, *Klebsiella-Enterobacter-Serratia* species, and *Citrobacter* species), and is used as an adjuvant treatment for infections caused by Gram-positive bacteria (e.g., *Staphylococcus* species) (1). Gentamicin may also be used topically to treat ophthalmic and dermatological infections.

In most patients, prolonged exposure to high gentamicin levels will cause ototoxicity (damage to the inner ear). However, in individuals who carry specific variants in the mitochondrial gene, *MT-RNR1*, a single dose of gentamicin can result in hearing loss. This toxicity occurs in genetically susceptible individuals even though the serum drug level is within therapeutic range (2).

In most studies, 100% of individuals with the *MT-RNR1* variant known as m.1555A>G (NC_012920.1:m.1555A>G) developed hearing loss after receiving aminoglycoside therapy. The onset of hearing loss varies, but once it occurs, the hearing loss is usually moderate to profound, bilateral, and irreversible (3).

Currently, the FDA-approved drug label for gentamicin does not include a statement about *MT-RNR1*. However, a 2014 American College of Medical Genetics and Genomics (ACMG) guideline includes the following recommendation: “Single-gene testing may be warranted in cases in which the medical or family history, or presentation of the hearing loss, suggests a specific etiology. For example, testing for mitochondrial DNA mutations associated with aminoglycoside ototoxicity may be considered for individuals with a history of use of aminoglycoside antibiotics” (4, 5).

Drug: Gentamicin

Aminoglycosides such as gentamicin are among the earliest formulations of antibiotics (6). They are effective against most aerobic bacteria, both Gram-positive and Gram-negative. But because they are inactive against anaerobes, they are often used in combination with another antibiotic, such as a beta-lactam antibiotic or a cephalosporin, to increase coverage (7).

Six aminoglycoside drugs are currently approved for use by the FDA: amikacin, gentamicin, neomycin, paromomycin, streptomycin, and tobramycin. The ending of these drug names, -mycin or -micin, reflects from which genus of bacteria the aminoglycoside was derived from, *Streptomyces* or *Micromonospora* respectively (8).

Aminoglycosides exert antibacterial effects by binding to bacterial ribosomes and inhibiting bacterial protein synthesis. They bind to the 30s ribosomal subunit, which interferes with the decoding site—this is where the ribosome has to accurately select tRNA in accordance with the appropriate mRNA codon. Errors here lead to inappropriate translation of the mRNA codons, so that incorrect amino acids are inserted into the polypeptide chain. This can disrupt elongation of the peptide chain (9, 10).

Like all aminoglycosides, gentamicin is poorly absorbed from the gut, so it is not taken orally. It is either given by injection, with regular blood tests to monitor drug levels, or given topically in the form of drops, cream, or ointment, to treat infections of the eye or skin.

The toxicity of aminoglycosides, along with the discovery of equally potent but less toxic antibiotics, has meant that the use of aminoglycoside injections is reserved for serious infections that are proven, or strongly suspected to be, caused by susceptible bacteria. Aminoglycosides are most commonly used in the treatment of neonatal septicemia, especially in premature babies—over 90% need aminoglycoside therapy during the first weeks of life (11). Aminoglycosides are also used in combination with other antibiotics as surgical prophylaxis in patients who are allergic to penicillin, and for febrile neutropenia, septic shock, and drug-resistant tuberculosis (6).

The main toxicities of aminoglycoside injections are kidney damage (nephrotoxicity) and damage to the inner ear (ototoxicity) (12). Nephrotoxicity primarily involves the proximal tubules and is generally reversible (13). In contrast, aminoglycoside-induced ototoxicity is usually irreversible. Damage may occur to the cochlea—resulting in sensorineural hearing loss—or the vestibular system—causing problems with balance, vertigo, ataxia, nausea, and vomiting. Gentamicin is considered to be more toxic to the vestibular system so is used for vestibular ablation to treat Ménière's disease. Amikacin and neomycin are examples of aminoglycosides that are more toxic to the cochlea (12, 14).

Rarely, neuromuscular blockade can occur after aminoglycoside therapy. The boxed warning on the FDA-approved drug label recommends that aminoglycosides “be used with caution in patients with neuromuscular disorders, such as myasthenia gravis or parkinsonism, because they may aggravate muscle weakness (7)”; whereas the British National Formulary states that aminoglycosides should not be given to patients with myasthenia gravis (15).

Gene: *MT-RNR1*

Mitochondria are the main source of energy in most cells—they use oxygen, sugars, and fats to create energy in the form of ATP. This process is known as oxidative phosphorylation. Any genetic variation that disrupts normal mitochondrial function can have severe effects on health.

Mitochondria have their own genome—it is small, circular, and resembles the bacterial prokaryotes from which they evolved. The mitochondrial genome is passed down from mother to child (maternal inheritance) and contains 37 genes, one of which is the *MT-RNR1* gene (“mitochondrially encoded 12S RNA”). The ribosomal RNA (rRNA) encoded by *MT-RNR1* is essential in the synthesis of the proteins that carry out oxidative phosphorylation.

Consistent with their bacterial origin, mitochondrial rRNA more closely resembles bacterial rRNA than human rRNA. However, at a highly conserved decoding region in the *MR-RNR1* gene, the sequence in humans is distinct from the sequence in bacteria. This difference means that aminoglycosides, which target the decoding region in bacteria, normally do not bind to this region in humans (9).

However, genetic variation in the ribosomal decoding region can result in mitochondrial RNA becoming more similar to bacterial rRNA, thereby facilitating the binding of aminoglycosides. The mechanism is unclear, but aminoglycosides damage the sensory hair cells in the cochlea that mediate hearing (16-18).

The most common *MT-RNR1* variant is a single nucleotide substitution of a guanine at position 1555 for an adenine (m.1555A>G). Individuals with this variant are exquisitely sensitive to aminoglycoside-induced hearing loss, which is moderate to profound, bilateral, irreversible, and may have a rapid onset. Even a single dose of aminoglycoside can be sufficient to cause ototoxicity (2, 19).

Genetically susceptible individuals who are not exposed to aminoglycosides may nonetheless develop hearing loss, referred to as “non-syndromic mitochondrial hearing loss.” The course of hearing loss may be affected by the presence of additional genetic factors as well as environmental factors, such as exposure to loud noise. However, normal hearing is usually preserved until at least 44 years of age (2).

The prevalence of the m.1555A>G variant varies among different populations. In the US, the population prevalence is estimated to be 0.09%, and in the UK, 0.20% (5, 20, 21). In hearing impaired populations, the prevalence is much greater, but the estimates vary widely based on study differences, such as the age of onset of hearing loss and whether there has been exposure to aminoglycosides. Estimates include a prevalence of 3.5% among the hearing impaired population in Japan (22), 5% among deaf individuals in Indonesia (23), and 6% of individuals with post-lingual hearing loss from the UK and Southern Italy (24). Additionally, a prevalence of 15% has been reported in “ethnically diverse patients in the United States with hearing loss after aminoglycoside exposure” (25), and in 15-20% of individuals from Spain with hearing loss (26).

The m.1555A>G variant is the most well studied *MT-RNR1* variant with regards to aminoglycoside ototoxicity, but other mitochondrial variants are also strongly associated with hearing loss. In 10 small studies, all individuals with the 1494C > T (NC_012920.1:m.1494C>T) variant developed hearing loss after receiving an aminoglycoside antibiotic. A 827A>G (NC_012920.1:m.827A>G) variant, and variants at position 961, have also been associated with non-syndromic hearing loss, both with and without the use of aminoglycosides (3).

Several studies have highlighted the complex issues raised by screening for pathogenic *MT-RNR1* variants. The aim of screening is to prevent avoidable hearing loss in genetically susceptible individuals by administering an alternative antibiotic whenever possible. Issues include the costs of universal screening, for example, as part of the newborn screening program—given that the prevalence of m.1555A>G is thought to be 1 in 385 Caucasians (2, 27, 28)—versus limiting genetic testing to a case-by-case basis (e.g., patients with tuberculosis, children with leukemia, individuals with cystic fibrosis, and surgical patients allergic to beta-lactam antibiotics)(5, 29).

In the US, aminoglycosides are most commonly used in the neonatal intensive care unit, where acute, life-threatening sepsis means that aminoglycoside therapy cannot be delayed to wait for the results of genetic testing (30). However, recent advances in screening has allowed for rapid, accurate and inexpensive testing (31-33). One potential alternative would be to screen all pregnant women, because mitochondrial variants are maternally inherited and m.1555A>G is almost always homoplasmic (“homoplasmy” is when all the mitochondrial DNAs in a cell are identical; when they are not, it is called “heteroplasmy”) (5, 19, 34).

Genetic screening may provide more benefit if aminoglycoside use becomes more widespread because of growing resistance to other antibiotics. Or screening could be reserved for countries where aminoglycosides are still commonly used, despite their toxicity, because they are inexpensive (35). In countries where the use of aminoglycosides is more common, a quarter of people with aminoglycoside-induced hearing loss have maternal relatives who also have drug-related hearing loss (36, 37).

A report from the World Health Organization’s Essential Medicines and Pharmaceutical Policies comments that “pre-treatment screening is an important consideration to prevent aminoglycoside related hearing loss but given cost and access issues, asking about a maternal family history of deafness may be more practical” (38).

Genetic Testing

The NIH's Genetic Testing Registry (GTR) provides examples of the genetic tests that are currently available for the *MT-RNR1* gene. Targeted mutation panels vary among testing laboratories, but most laboratories routinely test for m.1555A>G.

MT-RNR1 variants are associated with two conditions: aminoglycoside hypersensitivity resulting in post-exposure deafness and nonsyndromic mitochondrial hearing loss that tends to develop gradually over time. While the presence of an *MT-RNR1* variant indicates a high risk of aminoglycoside ototoxicity, the test results do not predict the age of onset or severity of nonsyndromic mitochondrial hearing loss (19).

Therapeutic Recommendations based on Genotype

Excerpt from the American College of Medical Genetics and Genomics (ACMG) Guideline for the Clinical Evaluation and Etiologic Diagnosis of Hearing Loss:

For individuals lacking physical findings suggestive of a known syndrome and having medical and birth histories that do not suggest an environmental cause of hearing loss, a tiered diagnostic approach should be implemented.

Pretest genetic counseling should be provided, and, with patient's informed consent, genetic testing should be ordered.

Single-gene testing may be warranted in cases in which the medical or family history, or presentation of the hearing loss, suggests a specific etiology. For example, testing for mitochondrial DNA mutations associated with aminoglycoside ototoxicity may be considered for individuals with a history of use of aminoglycoside antibiotics.

Please review the complete therapeutic recommendations that are located here: (4).

Nomenclature

Common allele name	Alternative names	HGVS reference sequence			dbSNP reference identifier for allele location
		Genomic	Coding	Protein	
m.1555A>G	A1555G	NC_012920.1:m.1555A>G	NA	NA (encodes ribosomal RNA)	rs267606617
m.1494C>T	C1494T	NC_012920.1:m.1494C>T	NA	NA (encodes ribosomal RNA)	rs267606619
m. 827A>G	A827G	NC_012920.1:m.827A>G	NA	NA (encodes ribosomal RNA)	rs28358569

Acknowledgments

The author would like to thank Shannon Manzi, PharmD, BCPPS, Director, Clinical Pharmacogenomics Service, Boston Children's Hospital, and Assistant Professor of Pediatrics, Harvard Medical School, for reviewing this summary.

2015 version:

The author would like to thank Stuart Scott, Assistant Professor of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai; Shamima Rahman, FRCP, PhD, Professor of Paediatric Metabolic Medicine at University College London and Honorary Consultant in Paediatric Metabolic Medicine at Great Ormond Street Hospital; and Maria Bitner-Glindzicz, FRCP, PhD, Professor of Clinical Molecular Genetics at University College London and Honorary Consultant in Clinical Genetics at Great Ormond Street Hospital.

Version History

To view the 2015 version of this summary (created: April 29, 2015) please click [here](#).

References

1. GENTAMICIN - gentamicin injection, solution [package insert]; November 2016. Available from: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be5b414e-d598-4721-80ee-5836156ad210>
2. Rahman S., Ecob R., Costello H., Sweeney M.G., et al. Hearing in 44-45 year olds with m.1555A>G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort study. *BMJ open*. 2012;2:e000411. PubMed PMID: 22223843.
3. Barbarino J.M., McGregor T.L., Altman R.B., Klein T.E. PharmGKB summary: very important pharmacogene information for MT-RNR1. *Pharmacogenet Genomics*. 2016 Dec;26(12):558–567. PubMed PMID: 27654872.
4. Alford R.L., Arnos K.S., Fox M., Lin J.W., et al. American College of Medical Genetics and Genomics guideline for the clinical evaluation and etiologic diagnosis of hearing loss. *Genet Med*. 2014 Apr;16(4):347–55. PubMed PMID: 24651602.
5. Bitner-Glindzicz M., Pembrey M., Duncan A., Heron J., et al. Prevalence of mitochondrial 1555A-->G mutation in European children. *The New England journal of medicine*. 2009 Feb 5;360(6):640–2. PubMed PMID: 19196684.
6. Poulikakos P., Falagas M.E. Aminoglycoside therapy in infectious diseases. Expert opinion on pharmacotherapy. 2013 Aug;14(12):1585–97. PubMed PMID: 23746121.
7. GENTAMICIN (gentamicin sulfate) injection, solution [package insert]; 2014 March 12. Available from: <http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a73a5453-c091-43fd-aae2-d992152363b1>
8. Procopio, R.E., Silva, I.R., Martins, M.K., Azevedo, J.L., et al., *Antibiotics produced by Streptomyces*. The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases, Sep-Oct, 2012. **16**(5): p. 466-71.
9. Demeshkina N., Jenner L., Westhof E., Yusupov M., et al. A new understanding of the decoding principle on the ribosome. *Nature*. 2012 Apr 12;484(7393):256–9. PubMed PMID: 22437501.
10. Tsai A., Uemura S., Johansson M., Puglisi E.V., et al. The impact of aminoglycosides on the dynamics of translation elongation. *Cell reports*. 2013 Feb 21;3(2):497–508. PubMed PMID: 23416053.
11. Soini H.K., Karjalainen M.K., Hinttala R., Rautio A., et al. Mitochondrial hearing loss mutations among Finnish preterm and term-born infants. *Audiol Res*. 2017 Jul 18;7(2):189. PubMed PMID: 29291046.
12. Forge A., Schacht J. Aminoglycoside antibiotics. *Audiology & neuro-otology*. 2000 Jan-Feb;5(1):3–22. PubMed PMID: 10686428.
13. Xie J., Talaska A.E., Schacht J. New developments in aminoglycoside therapy and ototoxicity. *Hearing research*. 2011 Nov;281(1-2):28–37. PubMed PMID: 21640178.
14. Ahmed R.M., Hannigan I.P., MacDougall H.G., Chan R.C., et al. Gentamicin ototoxicity: a 23-year selected case series of 103 patients. *The Medical journal of Australia*. 2012 Jun 18;196(11):701–4. PubMed PMID: 22554194.
15. *British National Formulary*. June 2014, BMJ Group and Pharmaceutical Press: London.
16. Guan M.X. Mitochondrial 12S rRNA mutations associated with aminoglycoside ototoxicity. *Mitochondrion*. 2011 Mar;11(2):237–45. PubMed PMID: 21047563.
17. Selimoglu E. Aminoglycoside-induced ototoxicity. *Current pharmaceutical design*. 2007;13(1):119–26. PubMed PMID: 17266591.
18. Bates D.E. Aminoglycoside ototoxicity. *Drugs of today*. 2003 Apr;39(4):277–85. PubMed PMID: 12743643.
19. Pandya, A., *Nonsyndromic Hearing Loss and Deafness, Mitochondria*, A.M. Pagon RA, Ardinger HH, et al., editors., Editor., University of Washington: Seattle (WA).

20. Vandebona H., Mitchell P., Manwaring N., Griffiths K., et al. Prevalence of mitochondrial 1555A-->G mutation in adults of European descent. *The New England journal of medicine*. 2009 Feb 5;360(6):642–4. PubMed PMID: 19196685.
21. Tang, H.Y., Hutcheson, E., Neill, S., Drummond-Borg, M., et al., *Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk?* *Genetics in medicine : official journal of the American College of Medical Genetics*, Sep-Oct, 2002. 4(5): p. 336-45.
22. Usami S., Abe S., Akita J., Namba A., et al. Prevalence of mitochondrial gene mutations among hearing impaired patients. *Journal of medical genetics*. 2000 Jan;37(1):38–40. PubMed PMID: 10633132.
23. Malik S.G., Pieter N., Sudoyo H., Kadir A., et al. Prevalence of the mitochondrial DNA A1555G mutation in sensorineural deafness patients in island Southeast Asia. *Journal of human genetics*. 2003;48(9):480–3. PubMed PMID: 12955586.
24. Jacobs H.T., Hutchin T.P., Kappi T., Gillies G., et al. *Mitochondrial DNA mutations in patients with postlingual, nonsyndromic hearing impairment*. *European journal of human genetics*. EJHG. 2005 Jan;13(1):26–33. PubMed PMID: 15292920.
25. Fischel-Ghodsian N., Prezant T.R., Chaltraw W.E., Wendt K.A., et al. Mitochondrial gene mutation is a significant predisposing factor in aminoglycoside ototoxicity. *American journal of otolaryngology*. 1997 May-Jun;18(3):173–8. PubMed PMID: 9164619.
26. Bravo O., Ballana E., Estivill X. Cochlear alterations in deaf and unaffected subjects carrying the deafness-associated A1555G mutation in the mitochondrial 12S rRNA gene. *Biochemical and biophysical research communications*. 2006 Jun 2;344(2):511–6. PubMed PMID: 16631122.
27. Linden Phillips L., Bitner-Glindzicz M., Lench N., Steel K.P., et al. The future role of genetic screening to detect newborns at risk of childhood-onset hearing loss. *International journal of audiology*. 2013 Feb;52(2):124–33. PubMed PMID: 23131088.
28. McLeod H.L., Isaacs K.L. Preemptive pharmacogenetic testing: insufficient data equal unsatisfactory guidance. *Annals of internal medicine*. 2011 Jun 21;154(12):842–4. PubMed PMID: 21690601.
29. Abusamra R., McShane D. Is deafness mutation screening required in cystic fibrosis patients? *Paediatr Respir Rev*. 2016 Aug;20 Suppl:24–6. PubMed PMID: 27427311.
30. Boles R.G., Friedlich P. Should patients be screened for 12S rRNA mutations before treatment with aminoglycosides? *Mitochondrion*. 2010 Jun;10(4):391–2. PubMed PMID: 20302974.
31. Ding Y., Xia B.H., Liu Q., Li M.Y., et al. Allele-specific PCR for detecting the deafness-associated mitochondrial 12S rRNA mutations. *Gene*. 2016 Oct 10;591(1):148–52. PubMed PMID: 27397648.
32. Yan D., Xiang G., Chai X., Qing J., et al. Screening of deafness-causing DNA variants that are common in patients of European ancestry using a microarray-based approach. *PLoS One*. 2017;12(3):e0169219. PubMed PMID: 28273078.
33. Wang X., Hong Y., Cai P., Tang N., et al. Rapid and Reliable Detection of Nonsyndromic Hearing Loss Mutations by Multicolor Melting Curve Analysis. *Sci Rep*. 2017 Feb 22;7:42894. PubMed PMID: 28225033.
34. Göpel W., Berkowski S., Preuss M., Ziegler A., et al. Mitochondrial mutation m.1555A>G as a risk factor for failed newborn hearing screening in a large cohort of preterm infants. *BMC Pediatr*. 2014 Aug 26;14:210. PubMed PMID: 25155176.
35. Jackson J., Chen C., Busing K. Aminoglycosides: how should we use them in the 21st century? *Current opinion in infectious diseases*. 2013 Dec;26(6):516–25. PubMed PMID: 24141453.
36. Hu D.N., Qui W.Q., Wu B.T., Fang L.Z., et al. Genetic aspects of antibiotic induced deafness: mitochondrial inheritance. *J Med Genet*. 1991 Feb;28(2):79–83. PubMed PMID: 2002491.
37. Bitner-Glindzicz M., Rahman S. Ototoxicity caused by aminoglycosides. *BMJ*. 2007 Oct 20;335(7624):784–5. PubMed PMID: 17947747.
38. Matthai, D.E. *Gentamicin - Ototoxicity in children in Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicine*. 2008 Geneva, Switzerland: World Health Organisation.

License

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons [Attribution 4.0 International \(CC BY 4.0\)](#) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.